| Period from April | ||||||||||||
| 12, 2002 | ||||||||||||
| (inception) | ||||||||||||
| Year ended | through | |||||||||||
| August 31, | August 31, | |||||||||||
| 2013 | 2012 | 2013 | ||||||||||
| Clinical trials | $ | 1,341,471 | $ | 1,298,310 | $ | 6,504,824 | ||||||
| Payroll and consulting fees | 447,195 | 385,646 | 2,368,728 | |||||||||
| Costs for registration of patents | 106,687 | 110,811 | 558,297 | |||||||||
| Compensation costs in respect of options granted to employees, directors and consultants | 346,961 | 98,688 | 3,268,842 | |||||||||
| Other | 338,635 | 160,350 | 886,242 | |||||||||
| Less - grants from the OCS and Bio Jerusalem Fund | (309,155 | ) | (372,959 | ) | (1,782,445 | ) | ||||||
| $ | 2,271,794 | $ | 1,680,845 | $ | 11,804,488 | |||||||